Table 5.
Recent published results using HDR to treat NMSC
| Author (reference) | No. of lesions | Follow-up (months) | Total dose/ fraction (Gy) | LC (%) | Acute side effects* | Late side effects* |
|---|---|---|---|---|---|---|
| Köhler-Brock [4] | 510 | 120 | NA | 91 | NA | NA |
| Guix [5] | 117 | 60 | 60-66/1.8 | 87 | G4 10% | G3 8% |
| Gauden [6] | 236 | 66 | 36/3 | 98 | G1 71% G2 34% | G3 5.5% |
| Maronas [8] | 51 | 45 | 48-57/4-3 | 89 | NA | NA |
| Pellizzon [11] | 13 | 36 | 20-60/3-6 | 80 | G1-2 30.8% | G2 23% |
| Delishaj [24] | 57 | 12 | 40-50/8-5 | 96.2 | G1-2 63.2% | G2 19.3% |
| Arenas [25] | 102 | 33 | 45-57/3 | 94.9 | G1-2 57.3% | G4 2.2% |
| Allan [26] | 13 | 18 | 45/5.6 | 100 | NA | NA |
| Montero [27] | 11 | 15 | 44-48/4 | 100 | NA | NA |
LC – local control, NA – not available
*
Side effects graded according to RTOG score [10]